What did @benross02 actually say?
This is a day-one log. The creator took MK-677, reported no sleep improvement, no appetite surge, but noted "a really, really good pump at the gym" and wondered out loud whether MK-677 caused it. That's pretty much it. No wild health claims, no dosing advice, no miracle promises. Just a guy journaling his first 24 hours on a compound most people in this space know as a growth hormone secretagogue.
To be fair to the creator, they were appropriately uncertain. "I don't know if that's MK now" is exactly the right thing to say on day one. The video is short, anecdotal, and framed as a personal update, not a tutorial. That context matters when we start pulling it apart.
Does the science back this up?
Here's the honest answer: a single day of MK-677 tells you almost nothing about whether the compound is working. MK-677, or ibutamoren, is an orally active ghrelin receptor agonist that stimulates pulsatile GH and IGF-1 secretion. The pharmacology is real. The timeline for meaningful effects is not 24 hours.
Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) showed that IGF-1 elevations from ibutamoren become statistically significant over weeks, not days. Sleep architecture changes, one of the more commonly reported effects, typically emerge after several days of use because they depend on shifts in slow-wave sleep that require consistent GH pulse augmentation over time. Patchett et al. (1995, PNAS) established the basic ghrelin-mimetic mechanism, but nothing in that literature suggests an acute pump response in a training session is a reliable pharmacological signal on day one. That pump was almost certainly the workout.
What did they get wrong (or right)?
Credit where it's due: the creator got more right than wrong here, mostly by saying very little with appropriate uncertainty. Not claiming the pump was definitely MK-677 was the right call. Not claiming sleep was improved on night one was honest, and actually aligns with reports that sleep quality can temporarily worsen or remain unchanged in the first few days.
What's missing, though, is context the audience probably needs. MK-677 is not a SARM despite being marketed alongside them constantly. It is not approved by the FDA for any indication in humans. It is not a research chemical with a light safety profile. Prolonged elevation of GH and IGF-1 carries real considerations, including potential effects on insulin sensitivity. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) documented increases in fasting blood glucose in subjects using ibutamoren long-term. That's not a trivial footnote. The creator doesn't mention any of this, which in a 81K-view video is a gap worth naming.
What should you actually know?
MK-677 works through a legitimate mechanism. It mimics ghrelin to stimulate GH release from the pituitary, and it is orally bioavailable, which is unusual in this class. The research is not fabricated. What it is, though, is incomplete. Most human trials have been small, industry-sponsored, or focused on elderly or deficient populations. Extrapolating those results to young, healthy gym-goers doing day-one self-experiments is a stretch.
Key points anyone watching this video should hold onto:
- Day-one subjective reports have essentially zero predictive value for whether a compound is working pharmacologically.
- The appetite increase often associated with MK-677 typically emerges within the first week, driven by the ghrelin receptor agonism. Not feeling it on day one is normal.
- Sleep changes, if they occur, are more likely to show up in the first one to two weeks, not night one.
- MK-677 is not approved for human use outside of clinical trials. Sourcing and purity of unregulated compounds are serious variables that no self-experiment can control for.
- Anyone using this compound without monitoring fasting glucose and IGF-1 levels is flying blind in a way that matters over a multi-week cycle.
The creator says they'll post a week's update. That's actually a more reasonable timeline to start drawing tentative conclusions, though even then, n=1 anecdote is not evidence.